Analysis of key genes and their functions in placental tissue of patients with gestational diabetes mellitus

Yuxia Wang¹, Haifeng Yu², Fangmei Liu² and Xiue Song*²

Abstract

Background: This study was aimed at screening out the potential key genes and pathways associated with gestational diabetes mellitus (GDM).

Methods: The GSE70493 dataset used for this study was obtained from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) in the placental tissue of women with GDM in relation to the control tissue samples were identified and submitted to protein-protein interaction (PPI) network analysis and subnetwork module mining. Functional enrichment analyses of the PPI network and subnetworks were subsequently carried out. Finally, the integrated miRNA–transcription factor (TF)–DEG regulatory network was analyzed.

Results: In total, 238 DEGs were identified, of which 162 were upregulated and 76 were downregulated. Through PPI network construction, 108 nodes and 278 gene pairs were obtained, from which chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, protein tyrosine phosphatase, receptor type C (PTPRC), and human leukocyte antigen (HLA) were screened out as hub genes. Moreover, genes associated with the immune-related pathway and immune responses were found to be significantly enriched in the process of GDM. Finally, miRNAs and TFs that target the DEGs were predicted.

Conclusions: Four candidate genes (viz., CXCL9, CXCL10, PTPRC, and HLA) are closely related to GDM. miR-223-3p, miR-520, and thioredoxin-binding protein may play important roles in the pathogenesis of this disease.

Keywords: Gestational diabetes mellitus, Differentially expressed genes, Protein-protein interaction network, Integrated regulatory network, Transcription factors

Background

Expectant mothers with gestational diabetes mellitus (GDM), a common pregnancy complication, have an increased risk of developing type 2 diabetes mellitus [1]. Over the past 20 years, the prevalence of GDM has doubled, affecting approximately 10% of pregnancies in the USA [2, 3]. Babies born to mothers with GDM are typically at a high risk for macrosomia, neonatal cardiac dysfunction, neonatal hypoglycemia, stillbirth, childhood obesity, and type 2 diabetes mellitus [4–6]. Given the worldwide prevalence and adverse outcomes of GDM, there is an urgent need to grasp the pathophysiology and pathogenesis of the disease [2].

Previous studies have suggested that GDM is caused by enhanced insulin resistance and pancreatic beta (β)-cell dysfunction [7], involving genes that are related to insulin signaling, insulin secretion, maturity-onset diabetes of the young, and lipid and glucose metabolism, to name a few [8, 9]. Subsequently, it was found that inflammatory pathways [10], metabolic disorder [11], oxidative stress [12], and vitamin D concentrations [13] were also related to GDM. Furthermore, some genetic alterations, such as those of the genes encoding β3-adrenergic receptor [14] and transcription factor 7-like 2 polymorphism [15], were also found to be associated with GDM. Moreover, GDM results in major changes in the expression profiles of placental genes, with a
significant increase in markers and mediators of inflammation [10]. Recently, several microarray studies have verified that the cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), estrogen receptor 1 (ESR1) [16], fibronectin 1 (FN1), and leptin (LEP) [17] genes were essential for the pathogenesis of GDM. However, because the genes related to GDM have not yet been fully identified, the biological processes underlying the pathogenesis of this disease remain unclear.

In this study, the gene expression profiles of placental tissue from women with GDM were compared with those of matched normal placental tissue by microarray analysis, to screen out differentially expressed genes (DEGs) in GDM. The identified DEGs were then submitted to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analyses to explore the crucial pathways of GDM. Additionally, a protein-protein interaction (PPI) network was constructed and subnetwork module mining was performed to seek out the candidate disease genes. Finally, microRNAs (miRNAs) and transcription factors (TFs) that target the candidate DEGs were identified and analyzed. The results from this study may lay the groundwork for future research on the pathogenesis of GDM.

Methods

Microarray analysis
The gene expression dataset GSE70493, which is based on the GPL17586 [HTA-2.0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version] platform, was downloaded from the National Center for Biotechnology Information’s Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/). This dataset comprised 63 placental tissue specimens collected from 32 cases of GDM and 31 matched pregnancies without maternal complications.

Data reprocessing
The probe-level data (CEL files) were converted to expression estimates by the Puma [18] and Oligo [19] packages in R, and the original expression dataset was processed into expression values using the robust multi-array average algorithm [20] with the default settings implemented in Bioconductor. The DEGs were identified with the limma [21] software package according to the expression values of the sample probes, and only those with a p-value of less than 0.01 were selected and annotated for further analysis.

GO and KEGG pathway enrichment analyses
To assess the functions and significantly enriched pathways of the DEGs, ClusterProfiler [22] was used to identify the overrepresented GO terms in the biological process (BP), cellular component (CC), and molecular function (MF) categories, as well as the KEGG pathway categories. The hypergeometric distribution threshold for these analyses was a p-value of < 0.05.

PPI network construction and subnetwork module mining
The Search Tool for the Retrieval of Interacting Genes (STRING, ver. 10.0, https://string-db.org/) [23] database was used to analyze functional interactions between the DEGs and other genes, under a confidence score threshold of > 0.4. The PPI network was established using Cytoscape (ver. 3.3.0, http://www.cytoscape.org/) [24]. Then, the topology of the network was analyzed, and the hub nodes in the network were obtained by calculating the average degree of each node. The average degree is the average number of edges connecting all the nodes in the network, measured by three indexes: degree centrality [25], betweenness centrality [26], and closeness centrality [27].

Molecular Complex Detection (MCODE) [28] is an automated method for searching molecular complexes with similar functions in large protein interaction networks. The MCODE (ver. 1.4.2, http://apps.cytoscape.org/apps/mcode) plugin of Cytoscape was used to analyze the subnetwork modules with similar functions in the original PPI network. Then, GO and KEGG pathway analyses of the subnetwork modules were performed to evaluate their functions.

Prediction of miRNAs and transcription factors that regulate the DEGs
The TFs associated with the DEGs were predicted by the position weight matrices from TRANSFAC and JASPAR in the Enrichr database [29], under the hypergeometric distribution threshold of p < 0.01. miRNAs associated with the DEGs were predicted by miRTarBase in the Enrichr database, under the hypergeometric distribution threshold of p < 0.01. On the basis of the miRNA–DEG regulatory network and TF–DEG regulatory network, the integrated DEG–miRNA–TF regulatory network was constructed using Cytoscape.

Results

Analysis of the differentially expressed genes
After the microarray analysis, the probes that were mapped to multiple genes were considered nonspecific and were removed, and only those with unique genes were distinguished as DEGs. In total, 238 DEGs (comprising 162 upregulated and 76 downregulated genes) were identified from the GDM placental tissue samples compared with the matching normal pregnant tissue samples (Fig. 1).

Functional enrichment analyses
Through GO analysis, the top 10 overrepresented GO terms in the BP, MF, and CC categories were identified on the basis of the p-value (Fig. 2a). In the BP category, the
overrepresented terms included the interferon-gamma-mediated signaling pathway, lymphocyte chemotaxis, antigen processing and presentation of exogenous peptide antigen, and lymphocyte chemotaxis. In the CC category, the major histocompatibility complex (MHC) proteins, endoplasmic reticulum membrane, coated vesicle membrane, and endocytic vesicle membrane terms were enriched. In the MF category, the most significantly enriched terms were antigen binding, chemokine receptor binding, and MHC protein complex binding. The most remarkable DEGs involved in those GO terms encoded the human leukocyte antigen (HLA), chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, chemokines (CCL3, CCL4L1, CCL4, and CCL8), and protein tyrosine phosphatase, receptor type C (PTPRC).

Through KEGG pathway enrichment analysis, the top 20 enriched pathways were identified on the basis of the p-value (Fig. 2b). The significantly enriched categories included pathways for allograft rejection, graft-versus-host disease, type 1 diabetes mellitus, autoimmune thyroid disease, inflammatory bowel disease, the Toll-like receptor signaling pathway, and Th1 and Th2 cell differentiation. The genes associated with those pathways were HLA, CXCL9, CXCL10, and PTPRC.

**PPI network and subnetwork module analyses**

From the PPI network analysis, 108 nodes and 278 gene pairs were acquired (Fig. 3) and the top 15 nodes according to the measured scores of the three centrality indexes were screened out (Table 1). Among these, PTPRC, CXCL9, and CXCL10 always ranked in the top 15 for each index, implying that these genes may play important roles in the progression of GDM.

Two significant modules with scores > 5 and nodes > 5 were isolated from the PPI network (Fig. 4). HLA was found to be spread all over module 1. Functional analysis of the DEGs in module 1 verified that the GO terms were strongly related to antigen processing presentation and autoimmune thyroid disease (Fig. 5a). In module 2, CXCL9 and CXCL10 with the higher degrees were involved in lymphocyte chemotaxis and the chemokine signaling pathway (Fig. 5b).

**Prediction of miRNAs and transcription factors that regulate the target genes**

The miRNAs and TFs that may regulate the target gene were obtained from the Enrichr database [29] (Table 2). The miRNA–DEG–TF regulatory network was constructed by integrating the DEGs with the DEG-related miRNAs and TFs,
Fig. 2 (See legend on next page.)
as shown in Fig. 6. The integrated network comprised five miRNAs, 73 DEGs (59 down-regulated and 14 up-regulated), and two TFs (thioredoxin-binding protein (TBP) and POU class 1 homeobox 1 (POU1F1)). Specifically, most of the DEGs were regulated by \( \text{miR-223-3p} \), \( \text{miR-520} \), and TBP.

**Discussion**

GDM describes the condition of abnormal sugar metabolism or potential decreased glucose tolerance before pregnancy and is confirmed during pregnancy [30–32]. It is a complex disease, being influenced by...
many factors such as the environment, society, and genes [33]. Moreover, genetic studies have suggested that multiple genes are involved in the disease [8]. In our study, DEGs in GDM and their enriched functions were screened out via bioinformatic analysis, and four key genes (viz., HLA, CXCL9, CXCL10, and PTPRC) were identified to be crucial to the disease. Moreover, miR-223-3p, miR-520, and TBP were found to be strongly linked to those DEGs, indicating their importance in GDM.

CXCL9 and CXCL10 are categorized as “inflammatory” chemokines. Shimada and coworkers postulated that the binding of CXCL10 to CXCR3 played a crucial role in the suppression of pancreatic β-cell proliferation [34]. Besides this, CXCL10 could interact with Toll-like receptor 4 to continuously activate c-Jun N-terminal kinases and protein kinase B (Akt), induce the cleavage of p21-activated protein kinase 2, and switch the Akt signal from proliferation to apoptosis, resulting in the suppression of pancreatic β-cell proliferation [35]. The present study demonstrated that CXCL10 was significantly enriched in the Toll-like receptor signaling pathway, leading us to speculate that it is a key gene that participates in the pathogenesis of GDM by regulating the progress of the Toll-like receptor signaling pathway. Although CXCL9 has similar functional and structural characteristics as CXCL10, it was reported that CXCL9 could not bind to Toll-like receptor 4 [36]. In this study, CXCL9 was significantly enriched in the cytokine signaling pathway and may thus play a critical role in the pathogenesis of GDM by regulating the inflammatory pathway.

HLA, the gene for the human MHC, plays a pivotal role in the antigen presentation of extracellular and intracellular peptides and the regulation of immune responses [37]. Compared with other regions of the human genome, the MHC genes on chromosome 6 are more associated with the susceptibility to common diseases like diabetes, and indeed many reports have shown that HLA gene variants are related to the predisposition to type 1 diabetes mellitus [38]. Additionally, although

| Gene     | Degree | Gene  | Betweenness | Gene  | Closeness |
|----------|--------|-------|-------------|-------|-----------|
| PTPRC    | 22     | SOD2  | 3911.9185   | C3    | 0.072248  |
| CXCL10   | 18     | C3    | 3533.4678   | CXCL10| 0.071716  |
| HLA-A    | 18     | MRPS16| 2901.8518   | CXCL9 | 0.07162   |
| HLA-DRB1 | 17     | PTPRC | 1506.8242   | CXCL11| 0.071096  |
| GBP1     | 16     | FOXO1 | 1442.8683   | CXCL13| 0.071096  |
| CXCL9    | 15     | DCN   | 1370.2727   | PTPRC | 0.07072   |
| HLA-C    | 15     | CTSK  | 1234.5901   | MRPS16| 0.070674  |
| B2M      | 15     | CXCL10| 1129.5261   | LYZ   | 0.070627  |
| HLA-E    | 15     | NDUF1 | 1000.009    | CD81  | 0.070526  |
| HLA-DQA2 | 13     | MGP   | 953.2142    | GNG11 | 0.07021   |
| HLA-F    | 13     | CXCL9 | 760.1234    | GBP1  | 0.070072  |
| HLA-DRB5 | 13     | HLA-DRB1| 755.0963   | CD86  | 0.070072  |
| HLA-B    | 13     | IGFBP7| 708.1684    | B2M   | 0.070026  |
| CD86     | 12     | RBM8A | 625.9798    | TAS2R3| 0.06998   |
| CXCL11   | 12     | IGFBP1| 538.0367    | P2RY14| 0.06998   |

Fig. 4 Two subnetwork modules of the differentially expressed genes. a Module 1 subnetwork diagram; b module 2 subnetwork diagram. The red square nodes represent upregulated genes; the blue round nodes represent downregulated genes.
type 2 diabetes mellitus is not an autoimmune disease or associated with the HLA gene, there is evidence that genes in the HLA region might have an influence on the genetic susceptibility to this metabolic disorder [39]. Importantly, Steinborn and colleagues found that GDM was related to an increased humoral immune response against HLA-class II antigens [40]. Our study highlights the importance of HLA in the progression of GDM, during which the gene is downregulated, and emphasizes that the autoimmune response is significantly associated with the disease pathogenesis.

PTPRC (CD45) has an essential role in lymphocyte development, antigen receptor signal transduction, and modulation of the signals emanating from integrin and cytokine receptors [41]. In diabetes mellitus, protein tyrosine phosphatases act as negative regulators of insulin signal transduction [42]. A previous study demonstrated that the homozygous deletion of protein tyrosine

Table 2 miRNAs and transcription factors (TFs) regulating DEGs

| Term       | Gene count | P-value    | Genes                                                                 |
|------------|------------|------------|----------------------------------------------------------------------|
| POU1F1     | 29         | 0.0027516  | CD86; GPR65; COX17; ROR8; GPR174; CCL8; AB313BP; CCL3; SLAMF7; OR5B12; FGL1; CD96; DNTA; LUM; ANKRRO22; SETD3B2; BTN3A3; GNG11; DCN; CXL10; CXL11; ZEB1; FAM115C; FABP4; ALDH1A2; ALDH1A1; SPATS2L; ETV28; CLEC4E |
| TBP        | 43         | 0.0072984  | CD86; COX17; CCH1; CLEF2; GPR65; Sema3A; FGL2; C10ORF88; PRSS23; EPS8; GPR174; IL1R1; ING3; CTF5; SH3BP5; SLAMF7; OR5B12; SLAMF6; FGL1; IL6; PELO; GPP1; HLA-DQA2; HLA-DQAg1; PNP; CND1; ANKRRO22; SETD3B2; OR5B12; HLA-F; PPAR9; BTD1; DOK1; CENP; FABP4; GPR183; ALDH1A2; CLEC4E; IL1B; FKBPS; DOR2 |
| hsa-miR-223-3p | 6         | 0.0011276  | ZEB1; Sema3A; CCL3; RAS2; MY19; FOXO1 |
| hsa-miR-614  | 2         | 0.0048044  | CRISPLD2; SOD2 |
| hsa-miR-6810-5p | 5         | 0.0087679  | KLD3C5; SAMD9; HLA-C; CIAPIN1; TLP |
| hsa-miR-520 g-3p | 11        | 0.0093275  | CXCL10; PNP; SAMD8; CRISPLD2; PRUNE2; SH3BP5; T01IP; ZBED1; HIST1H2B2B2M; FOXO1 |
| hsa-miR-520 h | 11        | 0.0098226  | CXCL10; PNP; SAMD8; CRISPLD2; PRUNE2; SH3BP5; T01IP; ZBED1; HIST1H2B2B2M; FOXO1 |
phosphatase 1B (PTP1B) in myocytes enhanced both the insulin-dependent activation of insulin receptor autophosphorylation and the tyrosine phosphorylation of insulin receptor substrates, and increased insulin sensitivity [43]. Moreover, it was shown that the expression of PTPRC was related to residual β-cell function in type 1 diabetes mellitus [44]. Our results reveal that PTPRC is likely to be a key gene that impacts GDM.

Because miR-223 was found to be significantly dysregulated in GDM, it was selected as a potential circulating biomarker for this disease [45]. Additionally, as a stress-related miRNA, miR-223 negatively regulated the cryopyrin-encoding gene NLRP3 and subsequently interleukin-1 beta production [46]. In our study, production of the TFs zinc finger E-box binding homeobox 1 (ZEB1) and Forkhead box O1 (FOXO1) was regulated by miR-223-3p. FOXO1, a target of insulin signaling, regulates metabolic homeostasis in response to oxidative stress. The interaction of FOXO1 with β-catenin could attenuate the WNT signaling pathway, which is involved in lipid metabolism and glucose homeostasis [47]. Besides this, FOXO1 was targeted by miR-520h and miR-520g-3p, which were speculated to influence insulin sensitivity in human white adipose tissue through their predicted effects on glucose metabolism [48]. ZEB1, a zinc finger TF, is associated with placental development. It was reported that ZEB1 cooperated with FOXO members to suppress B-lymphocyte proliferation [49]. TBP is a universal eukaryotic TF. It was found that the enhancement of TBP-2 expression caused impairment of glucose-induced insulin secretion and insulin sensitivity [50]. In the present study, TBP was found to regulate many HLA genes (HLA-DQA1, HLA-F, and HLA-DQA2), implying its indispensable role in GDM.

Conclusions
In conclusion, four immune-related DEGs of GDM (viz., HLA, CXCL9, CXCL10, and PRPTC) appeared to be associated with not only the autoimmune process but also residual β-cell function. miR-223-3p, miR-520 (i.e., miR-520h and miR-520g-3p), and TBP regulated most of the DEGs, especially cellular metabolism-related genes (FOXO1 and ZEB1). These results provide new insights into the mechanisms of GDM pathogenesis.
Abbreviations
BP: Biological process; CC: Cellular component; CYP1A1: Cytochrome P450, family 1, subfamily A, polypeptide 1; DEGs: Differentially expressed genes; FOXD1: Forkhead box D1; GDM: Gestational diabetes mellitus; GO: Gene Ontology, KEGG: Kyoto Encyclopedia of Genes and Genomes; MF: Molecular function; POLUIF1: POLUI class 1 homeobox 1; PPI: Protein-protein interaction; PTP1B: Protein tyrosine phosphatase 1B; PTPRC: Protein tyrosine phosphatase, receptor type C; TBP: Thioredoxin-binding protein; TF: Transcription factor; ZEB1: Zinc finger E-box-binding homeobox 1

Acknowledgements
Not applicable.

Authors’ contributions
Conception and design of the research: YW; acquisition of the data: HY; analysis and interpretation of the data: FL; drafting of the manuscript: YW; revision of the manuscript for important intellectual content: XS. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gynecology, Jinan Central Hospital, Jinan City 250013, Shandong Province, China. 2Department of Obstetrics, Jinan Central Hospital, No. 105 Jiefang Road, Lixia District, Jinan City 250013, Shandong Province, China.

Received: 11 October 2019 Accepted: 20 November 2019
Published online: 29 November 2019

References
1. Ziegler AG, Wallner M, Kaiser I, Rossbauer M, Harsunen MH, Lachmann L, Maier J, Winkler C, Hummel S. Long-term protective effect of lactation on the development of type 2 diabetes in women with recent gestational diabetes mellitus. Diabetes. 2012;61:3167–71.
2. Reece EA, Leguizamon G, Wiznitzer A. Gestational diabetes: the need for a common ground. Lancet. 2009;373:1789–97.
3. Yang J, Chi X, Lian D, Ye S, Zeng Z, Liu D, Zhuang C. Esophageal reconstruction: posterior mediastinal or retrosternal route. J Surg Res. 2016;201:364–9.
4. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005;115:485–91.
5. Catalano PM, Tzybir ED, Wolfe RR, Roman NM, Amini SB, Sims EA. Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women. Am J Obstet Gynecol. 1992;167:913–9.
6. Moore TR. Fetal exposure to gestational diabetes contributes to subsequent adult metabolic syndrome. Am J Obstet Gynecol. 1992;167:913–9.
7. Wang YH, Wu HH, Ding H, Li Y, Wang ZH, Li F, Zhang JP. Changes of insulin resistance and beta-cell function in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy period: a case-control study. J Obstet Gynecol Res. 2013;39:647–52.
8. Robaire J, Grant AM. The genetics of gestational diabetes mellitus evidence for relationship with type 2 diabetes mellitus. Genet Med. 2008;10:340–50.
9. Pappa KI, Gazouli M, Economou K, Daskalakis G, Anastasiou E, Anagnostou NP, Antsaklis A. Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecol Endocrinol. 2011;27:267–72.
10. Radaelli T, Varastehpour A, Catalano P, Hauguel-de Mouzon S. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes. 2003;52:2951–8.
11. Chen X, Scholl TO. Oxidative stress changes in pregnancy and with gestational diabetes mellitus. Curr Diab Rep. 2005;5:282–8.
12. Chou C-C, Nihm M, Zhou S, Tan A, Kawase A, Macias ES, Fishbein MC, Lin SF, Chen P-S. Intracellular calcium dynamics and anisotropic reentry in isolated canine pulmonary veins and left atrium. Circulation. 2005;111:2899–97.
13. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10:185–97.
14. Festa A, Krugluger W, Shmawa N, Hopmeier P, Haffner SM, Schomberth G. Trp64Arg polymorphism of the beta-adrenergic receptor gene in pregnancy association with mild gestational diabetes mellitus. J Clin Endocrinol Metab. 1999;84:1695–9.
15. Pagan A, Sabater-Molina M, Ola P, Prieto-Sanchez MT, Blanco-Carnero JE, Parrilla JJ, Gil A, Larque E. A gene variant in the transcription factor 7-like 2 (TCF7L2) is associated with an increased risk of gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol. 2014;180:77–82.
16. Zhang Q, He M, Wang J, Liu S, Cheng H, Cheng Y. Predicting of disease genes for gestational diabetes mellitus based on network and functional consistency. Eur J Obstet Gynecol Reprod Biol. 2015;186:91–6.
17. Su Y, Zhang Y. Identification of biological processes and genes for gestational diabetes mellitus. Arch Gynecol Obstet. 2015;292:635–40.
18. Liu X, Gao Z, Zhang L, Rattray M, Puma S. Improved uncertainty propagation methods for gene and transcript expression analysis. BMC Bioinformatics. 2013;14:1471–2105.
19. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26:2633–7.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Sherlock U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics. 2003;19:249–64.
21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK, Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:20.
22. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–7.
23. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:28.
24. Shannon P, Markel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
25. Opasahl T, Agneessens F, Skovsted J. Node centrality in weighted networks: generalizing degree and shortest paths. Soc Networks. 2010;32:245–51.
26. Cukierski WJ, Foran DJ. Using Betweenness centrality to identify manifold shortcuts. Proc IEEE Int Conf Data Min. 2008;1:294–8.
27. Du Y, Gao C, Chen X, Hu Y, Sadiq R, Deng Y. A new closeness centrality measure via effective distance in complex networks. Chaos. 2015;25:4916215.
28. Badar G, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:13.
29. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma’ayan A, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:1471–2105.
30. Surapapani T, Nikhart I, Nirmalakhandan N. Diagnostic effectiveness of 75 g oral glucose tolerance test for gestational diabetes in India based on the International Association of the Diabetes and Pregnancy Study Groups guidelines. Obstet Med. 2013;6:125–8.
31. Özyemsin J, Pivac M, Mulliqi Kotorqi V, Pavil Renar J, Ivanisievic M, Orskovski S. Prevalence of gestational diabetes mellitus according to IADPSG and NICE criteria. Int J Gynaecol Obstet. 2016;135:250–4.
32. Merzger BE, Lowe LP, Dyer AR, Trimble ER, Chauvarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.
33. Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C. Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines. Aust N Z J Obstet Gynaecol. 2011;51:26–30.
34. Shimada A, Morimoto J, Kodama K, Suzuki R, Okawa Y, Funae O, Kasuga A, Saruta T, Narumi S. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care. 2001;24:510–5.
35. Schulthess F, Paroni F, Sauter N, Shu L, Ribaux P, Haataja L, Strieter R, Oberholzer J, King C, Maedler K. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009;9:125–39.

36. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:887–92.

37. Bodis G, Toth V, Schwarting A. Role of human leukocyte antigens (HLA) in autoimmune diseases. Rheumatol Ther. 2018;7:018–0100.

38. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–92.

39. Rich SS, French LR, Sprafka JM, Clements JP, Goetz FC. HLA-associated susceptibility to type 2 (non-insulin-dependent) diabetes mellitus: the Wadena City health study. Diabetologia. 1993;36:234–8.

40. Steinborn A, Saran G, Schneider A, Fenis N, Sohn C, Schmitt E. The presence of gestational diabetes is associated with increased detection of anti-HLA-class II antibodies in the maternal circulation. Am J Reprod Immunol. 2006;56:124–34.

41. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003;21:107–37.

42. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem. 2007;14:1729–38.

43. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Rondinone CM, Valverde AM, Lorenzo M. Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance. Diabetes. 2007;56:104–13.

44. Akerman L, Ludvigsson J, Casas R. Low C-peptide levels and decreased expression of TNF and CD45 in children with high risk of type 1 diabetes. J Clin Immunol. 2013;33:1484–15.

45. Pillar N, Yaffe L, Hod M, Shomron N. The possible involvement of microRNAs in preeclampsia and gestational diabetes mellitus. Best Pract Res Clin Obstet Gynaecol. 2015;29:176–82.

46. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McNees IB, Hammerschmidt W, O'Neill LA, Masters SL. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol. 2012;189:3795–9.

47. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia. 2008;51:1771–80.

48. Capobianco V, Nardelli C, Ferrigno M, Iaffaldano L, Pîone V, Forestieri P, Zambonaro N, Sacchetti L. miRNA and protein expression profiles of visceral adipose tissue reveal miR-141/YWHAG and miR-520e/RAB11A as two potential miRNA/protein target pairs associated with severe obesity. J Proteome Res. 2012;11:3358–69.

49. Chen J, Yusuf I, Andersen HM, Fruman DA. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J Immunol. 2006;176:2711–21.

50. Masutani H, Yoshihara E, Masaki S, Chen Z, Yodoi J. Thioredoxin binding protein (TBP)-2/Txnip and alpha-arrestin proteins in cancer and diabetes mellitus. J Clin Biochem Nutr. 2012;50:23–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.